Feedback / Questions
lirentelimab (AK002) - Allakos
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
http://www.ncbi.nlm.nih.gov/pubmed/35983569
Aug 21, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next